Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Altman

Showing results (281-290 of 365) with videos related to

Pageof 37
Sort By:
The American Journal of Cardiology|May 29, 2012
Usefulness of hemoglobin A(1c) to predict outcome after cardiac resynchronization therapy in patients with diabetes mellitus and heart failureRavi V Shah, Robert K Altman, Mi Young Park, et al.
The Journal of Biological Chemistry|February 9, 2017
Central Regulatory Role for SIN1 in Interferon γ (IFNγ) Signaling and Generation of Biological ResponsesBarbara Kroczynska, Gavin T Blyth, Robert L Rafidi, et al.
Heart Rhythm|August 10, 2014
Progressive ventricular dysfunction among nonresponders to cardiac resynchronization therapy: baseline predictors and associated clinical outcomesDaniel J Friedman, Gaurav A Upadhyay, Alefiyah Rajabali, et al.
Blood Cancer Journal|February 4, 2017
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromesR T Swords, J Watts, H P Erba, et al.
Molecular Cancer|June 10, 2010
Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acidMolly K Altman, Vashisht Gopal, Wei Jia, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2007
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphomaA M Evens, J K Altman, B B Mittal, et al.
Bioorganic & Medicinal Chemistry|July 21, 2015
Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanomaMandi M Murph, Guowei W Jiang, Molly K Altman, et al.
Leukemia & Lymphoma|April 24, 2013
Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney diseaseAli Tabarroki, Valeria Visconte, Heesun J Rogers, et al.
Blood Cancer Journal|November 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guideWei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, et al.
Pageof 37

Showing results (281-290 of 365) with videos related to

Sort By:
Pageof 37
The American Journal of Cardiology|May 29, 2012
Usefulness of hemoglobin A(1c) to predict outcome after cardiac resynchronization therapy in patients with diabetes mellitus and heart failureRavi V Shah, Robert K Altman, Mi Young Park, et al.
The Journal of Biological Chemistry|February 9, 2017
Central Regulatory Role for SIN1 in Interferon γ (IFNγ) Signaling and Generation of Biological ResponsesBarbara Kroczynska, Gavin T Blyth, Robert L Rafidi, et al.
Heart Rhythm|August 10, 2014
Progressive ventricular dysfunction among nonresponders to cardiac resynchronization therapy: baseline predictors and associated clinical outcomesDaniel J Friedman, Gaurav A Upadhyay, Alefiyah Rajabali, et al.
Blood Cancer Journal|February 4, 2017
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromesR T Swords, J Watts, H P Erba, et al.
Molecular Cancer|June 10, 2010
Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acidMolly K Altman, Vashisht Gopal, Wei Jia, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2007
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphomaA M Evens, J K Altman, B B Mittal, et al.
Bioorganic & Medicinal Chemistry|July 21, 2015
Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanomaMandi M Murph, Guowei W Jiang, Molly K Altman, et al.
Leukemia & Lymphoma|April 24, 2013
Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney diseaseAli Tabarroki, Valeria Visconte, Heesun J Rogers, et al.
Blood Cancer Journal|November 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guideWei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, et al.
Pageof 37